Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Multiple myeloma gammopathies

Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy

Leukemia volume 34, pages 3088–3090 (2020)Cite this article

Subjects

Signaling lymphocyte activation molecule family member 7 (SLAMF7) is a type I transmembrane protein expressed on myeloma cells and a subset of immune cells [1]. Based on the unique expression profile of SLAMF7, the monoclonal antibody elotuzumab was developed and is approved for patients with multiple myeloma (MM) in the USA, EU, and Japan [2,3,4]. Elotuzumab exhibits antimyeloma activity in combination with either of the immunomodulating drugs (IMiDs) lenalidomide or pomalidomide, and its mechanism of action (MoA) is thought to promote antibody-dependent cellular cytotoxicity by natural killer (NK) cells and NK cell activation [5, 6]. Despite the MoA, elotuzumab monotherapy did not show enough efficacy in a phase 1 clinical trial; no patients exhibited complete response, very good partial response, or partial response, but 26.5% of patients exhibited stable disease [7], suggesting an additional, NK cell system-independent, MoA for the antimyeloma activity of elotuzumab.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Fig. 1: Potential of sSLAMF7 as a predictive biomarker for multiple myeloma and elotuzumab treatment.

References

  1. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–84.

    CAS  Article  Google Scholar 

  2. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl J Med. 2015;373:621–31.

    CAS  Article  Google Scholar 

  3. Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–22.

    CAS  Article  Google Scholar 

  4. Taniwaki M, Yoshida M, Matsumoto Y, Shimura K, Kuroda J, Kaneko H. Elotuzumab for the treatment of relapsed or refractory multiple myeloma, with special reference to its modes of action and SLAMF7 signaling. Mediterr J Hematol Infect Dis. 2018;10:e2018014.

    Article  Google Scholar 

  5. Dong Z, Cruz-Munoz ME, Zhong MC, Chen R, Latour S, Veillette A. Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. Nat Immunol. 2009;10:973–80.

    CAS  Article  Google Scholar 

  6. Guo H, Cruz-Munoz ME, Wu N, Robbins M, Veillette A. Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Mol Cell Biol. 2015;35:41–51.

    Article  Google Scholar 

  7. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120:552–9.

    CAS  Article  Google Scholar 

  8. Postelnek J, Neely RJ, Robbins MD, Gleason CR, Peterson JE, Piccoli SP. Development and validation of electrochemiluminescence assays to measure free and total sSLAMF7 in human serum in the absence and presence of elotuzumab. AAPS J. 2016;18:989–99.

    CAS  Article  Google Scholar 

  9. Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, et al. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia. 2020;34:180–95.

    CAS  Article  Google Scholar 

  10. Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, et al. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. Int J Hematol. 2020;111:65–74.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This study was funded by Bristol-Myers Squibb K.K. English editing and formatting for journal submission was supported by Caudex, funded by Bristol-Myers Squibb K.K.

Author information

Author notes

  1. These authors contributed equally: Atsushi Suzuki, Satoshi Kakugawa, Masafumi Miyoshi

Affiliations

  1. Bristol-Myers Squibb K.K., Shinjuku, Tokyo, Japan

    Atsushi Suzuki, Satoshi Kakugawa & Masafumi Miyoshi

  2. Department of Hematology, Ibaraki Prefectural Central Hospital, Kasama, Japan

    Mitsuo Hori

  3. Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan

    Kenshi Suzuki

  4. Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan

    Yusuke Furukawa

  5. Hematology Ohta Clinic, Shinsaibashi, Osaka, Japan

    Kensuke Ohta

Authors
  1. Atsushi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoshi Kakugawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masafumi Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mitsuo Hori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenshi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yusuke Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kensuke Ohta
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AS prepared manuscript; AS, SK, and MM collected and analyzed data from CA204-116 study; MH, KS, and KO contributed CA204-116 study execution and data analysis, and YF supported and directed sSLAMF7 analysis.

Corresponding author

Correspondence to Atsushi Suzuki.

Ethics declarations

Conflict of interest

AS, SK, and MM are employees of Bristol-Myers Squibb K.K. MH reports postmarketing surveillance study fees from Celgene, Fujifilm RI Pharma, and Shire Japan. KS reports personal fees from Bristol-Myers Squibb K.K., Celgene, Janssen Pharmaceutical, Novartis, Sanofi, and Takeda. YF is supported by Grant-in-Aid for Scientific Research from JSPS, Ministry of Education, Culture, Sports, Science and Technology-supported program for the Strategic Foundation at Private Universities, Japan Leukemia Research Fund, Yasuda Memorial Cancer Foundation, Novartis Foundation, and Takeda Foundation. KO reports honoraria from Bristol-Myers Squibb K.K., Celgene K.K., Janssen Pharmaceutical K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co. Ltd.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Suzuki, A., Kakugawa, S., Miyoshi, M. et al. Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Leukemia 34, 3088–3090 (2020). https://doi.org/10.1038/s41375-020-0860-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-020-0860-7

Search

Advanced search

Quick links